New milestone reached in our understanding of the mechanism of action of EPs® 7630!
Two recently published preclinical studies boost the understanding of the potential mechanism of action of the Pelargonium sidoides extract EPs® 7630 and show the benefit of joint research projects with academia in the area of phytopharmaceuticals.
“We are excited by the success of our scientific collaborations with high level academic experts that has led to this set of important new insights with next level preclinical confirmation of antiviral activity and the identification of a completely new pharmacological activity of our EPs® 7630 ” states Dr. Martin Lehner, Director Preclinical R&D within the Schwabe Group.
Research conducted by the group of Prof. Michael Roth from the University Hospital Basel demonstrated for the first time the promotion of wound repair and cell regeneration by EPs® 7630 in models with human airway epithelial cells after rhinovirus infection ->
In addition, in another collaboration, the antiviral and immunomodulatory activity of EPs® 7630 under laboratory conditions against SARS-CoV-2 has now been confirmed in primary human respiratory epithelial cells and with various virus variants of concern such as Omicron ->
"The peer-reviewed publication of the two studies confirms our strategy at Dr. Willmar Schwabe to continuously advance the development of our evidence-based herbal medicines through our own research activities and collaborations with high-ranking academic partners and is an incentive to continue to consistently implement this path," emphasizes Dr. Dirk Bredenbröker, EVP R&D of the Schwabe Group
Disclaimer: “Since clinical studies have not been carried out, no statement can yet be made on the specific application in humans to prevent or treat COVID-19.